ELVN
Enliven Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$59.32
−0.55%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 60.0K | 263.0K | — | — | — |
| Gross Profit | (60.0K) | (263.0K) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 89.2M | 85.9M | 80.8M | 64.6M | 31.0M |
| SG&A Expense | 35.3M | 33.8M | 23.8M | 19.0M | 7.8M |
| General & Admin Expense | 35.3M | 33.8M | 23.8M | 19.0M | 7.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 124.4M | 119.4M | 104.6M | 83.5M | 38.8M |
| Cost and Expenses | 124.4M | 119.7M | 104.6M | 83.5M | 38.8M |
| Operating Income (EBIT) | (124.4M) | (119.7M) | (104.6M) | (83.5M) | (38.8M) |
| Non-Operating | |||||
| Interest Income | 18.5M | 16.0M | 14.9M | 12.0M | 1.1M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 18.5M | 16.0M | 14.9M | 12.0M | 1.1M |
| Other Non-Op Income/Expense | 18.5M | 16.0M | 15.8M | 11.9M | 1.1M |
| Non-Operating Income (excl Interest) | (18.5M) | (16.0M) | (15.8M) | (11.9M) | (1.1M) |
| EBT (Pre-Tax Income) | (105.9M) | (103.7M) | (88.8M) | (71.6M) | (37.7M) |
| Income Tax Expense | — | — | 232.0K | — | — |
| Bottom Line | |||||
| Net Income | (105.9M) | (103.7M) | (89.0M) | (71.6M) | (37.7M) |
| Earnings from Cont. Ops | (105.9M) | (103.7M) | (89.0M) | (71.6M) | (37.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (105.9M) | (103.7M) | (89.0M) | (71.6M) | (37.7M) |
| Per Share | |||||
| Basic EPS | ($1.64) | ($1.83) | ($1.89) | ($2.01) | ($6.03) |
| Diluted EPS | ($1.64) | ($1.83) | ($1.89) | ($2.01) | ($6.03) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 66.2M | 56.7M | 47.1M | 35.5M | 6.2M |
| Diluted Shares Outstanding | 66.2M | 56.7M | 47.1M | 35.5M | 6.2M |
| Profitability Metrics | |||||
| EBITDA | (105.8M) | (103.4M) | (88.5M) | (71.3M) | (37.4M) |
| D&A | 122.0K | 263.0K | 317.0K | 297.0K | 215.0K |
| EBIT | (105.9M) | (103.7M) | (88.8M) | (71.6M) | (37.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026